Development of an Intervention to Enhance Cancer Pain Management

Status Active, not recruiting

Clinical Trial Summary

This research study is being done to understand how patients with chronic cancer pain take their long-acting opioid medications, and to develop an intervention to enhance cancer pain management.

Clinical Trial Description

Long-acting opioids are a common treatment for cancer pain. The purpose of this study is to develop a program for patients who are taking a prescribed long-acting opioid for their cancer pain. Participants will be enrolled in this study at the Massachusetts General Hospital Cancer Center. This 14-week study involves completing a set of questionnaires at three different times during the study period. . During the study period, participants will use electronic pill caps to monitor their pain medication taking. They also will attend a series of three visits with one of the nurse practitioners on their care cancer team. The visits will focus on learning and practicing skills for managing cancer pain. The information that the investigators collect will help identify whether the sessions are feasible and useful to patients during the course of treatment for cancer pain. This trial will consist of two parts: Part 1: This is a single-group prospective observational study. Investigators will use quantitative and qualitative methods to examine rates, predictors and outcomes of adherence to LA opioids over a period of approximately eight weeks. This information will be used to inform Part 2 intervention development and testing. Part 2: Investigators will test the behavioral intervention in a non-randomized open pilot, over a period of approximately six weeks. Intervention process data, psychosocial and medical data, and post-intervention feedback will be collected to assess feasibility and acceptability. In an iterative process, ongoing data from exit interviews and therapist experience will be used to modify the intervention protocol. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03752268
Study type	Interventional
Source	Massachusetts General Hospital
Contact
Status	Active, not recruiting
Phase	N/A
Start date	April 15, 2014
Completion date	November 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04340024` - Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
Active, not recruiting	`NCT03609177` - Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly	N/A
Active, not recruiting	`NCT04591431` - The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy	Phase 2
Recruiting	`NCT06103669` - Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)	N/A
Recruiting	`NCT04585750` - The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)	Phase 1/Phase 2
Recruiting	`NCT03160274` - Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Completed	`NCT03736746` - Testing Feasibility of Motivational Interviewing for Patient-Reported Cancer Pain Goals	N/A
Completed	`NCT03638453` - Pilot Feasibility of the Pediatric Cancer Resource Equity (PediCARE) Intervention	N/A
Active, not recruiting	`NCT03850912` - Symptom Management Implementation of Patient Reported Outcomes in Oncology	N/A
Completed	`NCT03392090` - SHARE (Sharing Goals and Preferences) Study	N/A
Completed	`NCT03244826` - Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation	N/A
Recruiting	`NCT03517332` - Circulating Tumor DNA Exposure in Peripheral Blood
Completed	`NCT03721926` - A Geriatric Oncology Collaborative Care Intervention for Older Adults With Advanced Cancer	N/A
Active, not recruiting	`NCT03967379` - Multimodal Mobile Intervention Application (App) to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors	N/A
Completed	`NCT05176860` - Evaluation of Novel Cone-Beam CT for Guidance and Adaptation of Precision Radiotherapy	N/A
Active, not recruiting	`NCT03674047` - Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)	Phase 2